Loading clinical trials...

COMPLETEDPhase 4NCT04814355

The Effect of Celecoxib on Neuroinflammation in MDD

Major depressive disorder (MDD) affects an estimated 350 million people worldwide and is a leading contributor to global disease burden. Commonly used monoamine reuptake-inhibiting treatments for depr...

Lead sponsor: Stony Brook University•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Related studies

RECRUITINGPhase 2

Dextromethorphan-Bupropion on Striatal Activity in Adults With Major Depressive Disorder

NCT07523048 · Major Depressive Disorder (MDD)

RECRUITINGPhase 2

Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

NCT07226661 · Major Depressive Disorder (MDD)

RECRUITINGPhase 2

A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

NCT07115329 · Major Depressive Disorder

RECRUITINGPhase 3

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

NCT06793397 · Major Depressive Disorder (MDD), Depression in Adults, and more

RECRUITINGPhase 2

Topical Ketotifen 0.25% for Secondary Vestibulodynia

NCT07257029 · Provoked Vestibulodynia, Secondary Provoked Vestibulodynia, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 24, 2026Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE4

Enrollment41

Start dateAug 2018

Last updatedApr 24, 2026

Condition

Major Depressive Disorder Neuroinflammation

Locations shown

Psychiatry Department at Stony Brook University

Stony Brook, New York

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 24, 2026Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Effect of Celecoxib on Neuroinflammation in MDD

What this study is about

Clareo turns complex medical information into clear understanding you can use.

Sponsors

Related studies

Dextromethorphan-Bupropion on Striatal Activity in Adults With Major Depressive Disorder

Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

Topical Ketotifen 0.25% for Secondary Vestibulodynia

Trial snapshot

Condition

Locations shown

For caregivers